Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway

Cardiovascular Research

Volumn 87, Issue 4, 2010, Pages 656-664

  Horie, Takahiro ^a   Ono, Koh ^a   Nishi, Hitoo ^a   Nagao, Kazuya ^a   Kinoshita, Minako ^a   Watanabe, Shin ^a   Kuwabara, Yasuhide ^a   Nakashima, Yasuhiro ^a   Takanabe Mori, Rieko ^b   Nishi, Eiichiro ^a   Hasegawa, Koji ^b   Kita, Toru ^c   Kimura, Takeshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Cardiomyocyte; MicroRNA; Neuregulin

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LUCIFERASE; MICRORNA; NEU DIFFERENTIATION FACTOR; PROTEIN MIR 146 A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDIOTOXICITY; CELL DEATH; CONTROLLED STUDY; HEART MUSCLE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; CARDIOMYOPATHIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MUTATION; MYOCYTES, CARDIAC; NEUREGULINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 77955891306     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq148     Document Type: Article

References (39)

1. Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol 2008;88:11-17.
2. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838-5847.
3. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998;273: 10261-10269.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
5. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-2467. (Pubitemid 26151185)
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
7. Feng SM, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K et al. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol Cell Biol 2009;29:892-906.
8. Schroen B, Heymans S. MicroRNAs and beyond: the heart reveals its treasures. Hypertension 2009;54:1189-1194.
9. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008;105:2111-2116.
10. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, Medvid R et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 2009;105:585-594.
11. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007;129:303-317.
12. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22:3242-3254.
13. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009;460:529-533.
14. Iarussi D, Indolfi P, Casale F, Coppolino P, Tedesco MA, Di Tullio MT. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem 2001;8:1649-1660.
15. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007;116:506-514.
16. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69:1279-1283.
17. Perry MM, Williams AE, Tsitsiou E, Larner-Svensson HM, Lindsay MA. Divergent intracellular pathways regulate interleukin-1beta-induced miR-146a and miR-146b expression and chemokine release in human alveolar epithelial cells. FEBS Lett 2009;583:3349-3355.
18. Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008;283:31315-31322.
19. Horie T, Ono K, Nagao K, Nishi H, Kinoshita M, Kawamura T et al. Oxidative stress induces GLUT4 translocation by activation of PI3-K/Akt and dual AMPK kinase in cardiac myocytes. J Cell Physiol 2008;215:733-742.
20. Nishi H, Ono K, Iwanaga Y, Horie T, Nagao K, Takemura G et al. MICRORNA-15B modulates cellular ATP levels and degenerates mitochondria via ARL2 in neonatal rat cardiac myocytes. J Biol Chem 2010;285:4920-4930.
21. Nagao K, Ono K, Iwanaga Y, Tamaki Y, Kojima Y, Horie T et al. Neural cell adhesion molecule is a cardioprotective factor up-regulated by metabolic stress. J Mol Cell Cardiol 2010;48:1157-1168.
22. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006; 113:2211-2220.
23. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170:1831-1840.
24. Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009;284:2080-2087.
25. Horie T, Ono K, Nishi H, Iwanaga Y, Nagao K, Kinoshita M et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 2009;389:315-320.
26. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009;10:578-585.
27. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4:721-726.
28. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardio-myopathy. Proc Natl Acad Sci USA 2002;99:8880-8885.
29. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-465.
30. Garcia-Rivello H, Taranda J, Said M, Cabeza-Meckert P, Vila-Petroff M, Scaglione J et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 2005;289:H1153-H1160.
31. Liu FF, Stone JR, Schuldt AJ, Okoshi K, Okoshi MP, Nakayama M et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 2005;289:H660-H666.
32. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-7826.
33. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 2002;367:729-740.
34. Schulze-Osthoff K, Los M, Baeuerle PA. Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. Biochem Pharmacol 1995;50:735-741.
35. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. IkappaB kinase-independent Ikap-paBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 2003;23:8070-8083.
36. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
37. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007;116:954-960.
38. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-231.
39. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 1996;271:19029-19032.